[1] RUSSELL SJ, PENG KW, BELL JC.Oncolytic viro therapy[J]. Nat Biotechnol, 2012, 30(7): 658-670. [2] TWUMASI-BOATENG K, PETTIGREW JL, KWOK YYE, et al.Oncolytic viruses as engineering platform for combination immunotherapy[J]. Nat Rev Cancer, 2018, 18(7): 419-432. [3] LIN Q, WANG DG, ZHANG ZQ, et al.Applications of virus vector-mediated gene therapy in China[J]. Hum Gene Ther, 2018, 29(2): 98-109. [4] DUNBAR CE, HIGH KA, JOUNG JK, et al. Gene therapy comes of age[J]. Science, 2018, 359(6372): aan4672. [5] LIMA BS, VIDEIRA MA.Toxicology and biodistribution: the clinical value of animal biodistribution studies[J]. Mol Ther Methods Clin Dev, 2018, 8: 183-197. [6] ZHANG M, GONG XJ, YE X, et al.IPRP considerations on the biodistribution of gene therapy products[J]. Cent South Pharm(中南药学), 2019, 17(7): 993-996. [7] HAWORTH R, PILLING AM.The PCR assay in the preclinical safety evaluation of nucleic acid medicines[J]. Hum Exp Toxicol, 2000, 19(5): 267-276. [8] JOHNSON G, NOUR AA, NOLAN T, et al.Minimum Information necessary for quantitative real- time PCR experiments[J]. Methods Mol Biol, 2014, 1160: 5-17. [9] WANG X, GENG XC, XU MZ.Discussions on the detection strategy and method for bio-distribution of gene therapy medicine[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(11): 997-1000. [10] SEITZRE J, ZHANG H, KOSER M, et al.Effect of biological matrix and sample preparation on qPCR quantitation of siRNA drugs in animal tissues[J]. J Pharmacol Toxicol Methods, 2011, 63(2): 168-173. [11] HO JK, WHITE PJ, POUTON CW.Tissue-specific calibration of real-time PCR facilitates absolute quantification of plasmid DNA in biodistribution studies[J]. Mol Ther Nucleic Acids, 2016, 5(10): e371. [12] FU J, LI D, XIA S, et al.Absolute quantification of plasmid DNA by real-time PCR with genomic DNA as external standard and its application to a biodistribution study of an HIV DNA vaccine[J]. Anal Sci, 2009, 25(5): 675-680. [13] TIAN C, LIU J, ZHOU H, et al.Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody[J]. Cancer Lett, 2021, 518: 49-58. [14] ANDTBACKA RH, KAUFMAN HL, COLLICHIO F, et al.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. J Clin Oncol, 2015, 33(25): 2780-2788. [15] BOLOVAN CA, SAWTELL NM, THOMPSON RL.ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell culture[J]. J Virol, 1994, 68(1): 48-55. [16] LANGFORD G, DAYAN A, YLA-HERTTUALA S, et al.A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration[J]. J Gene Med, 2009, 11(6): 468-476. [17] THOMAS CE, EHRHARDT A, KAY MA.Progress and problems with the use of viral vectors for gene therapy[J]. Nat Rev Genet, 2003, 4(5): 346-358. [18] WANG X, WANG C, QU Z, et al.Preclinical safety assessment of toxicity and biodistribution of oncolytic virus HSV-1 express human PD-1 antibody in mice[J]. Regul Toxicol Pharmacol, 2022, 132: 105166. [19] WANG X, MIAO YF, HUO Y, et al.Pre-clinical evaluation of oncolytic virus drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(6): 597-600. [20] FDA. Guidance for Industry: preclinical assessment of investigational cellular and gene therapy products[EB/OL]. (2012-11)[2022-04-21]. https://www.fda.gov/media/87564/download. [21] ICH. S12: Nonclinical biodistribution considerations for gene therapy products[EB/OL]. (2021-10-01)[2022-04-21].https://database.ich.org/sites/default/files/ICH_S12_Step2_DraftGuideline_2021_0603.pdf. |